A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Progressive Pulmonary Fibrosis

To join this study, you must have a diagnosis of progressive pulmonary fibrosis that has shown signs of getting worse in the last two years. Doctors will confirm this using detailed lung scans.

If you are already taking certain medications for your lung condition, like pirfenidone, nintedanib, or other similar drugs (e.g., mycophenolate mofetil, azathioprine, tacrolimus, or some arthritis medications like methotrexate or specific biologics), you might still be able to join. However, you must have been on a stable dose of these medications for at least three months before the study starts. If you've recently stopped taking any of these, there might be a waiting period.

There are also some reasons why you wouldn't be able to join, such as having a specific type of lung fibrosis called Idiopathic Pulmonary Fibrosis with UIP confirmed at the start of the study, or if you've had a stroke or a mini-stroke (TIA). All participants, both men and women, will need to agree to use effective birth control methods if there's any chance of pregnancy.

Taking part in this study means you will receive either the study medication (BMS-986278) or a placebo. You won't know which one you are getting, and neither will your study doctor. You'll have regular visits to the clinic for medical check-ups, blood tests, and lung function tests to see how you're responding to the treatment.

These visits will help measure the effectiveness of the drug and monitor for any side effects. You'll also be asked about your health and any changes you notice. The study involves taking the medication as prescribed and attending all scheduled appointments. The total duration of your participation, including follow-up, will be explained in detail by the study team.